Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
10/2012
10/18/2012US20120263744 Compositions And Methods Involving Respiratory Syncytial Virus Subgroup B Strain 9320
10/18/2012US20120263743 Influenza hemagglutinin compositions and uses thereof
10/18/2012US20120263742 Combination of Protein Forms for Hornfly Vaccination
10/18/2012US20120263741 Variants of the major allergen phl p 1 from timothy grass
10/18/2012US20120263740 Aptamer-targeted sirna to inhibit nonsense mediated decay
10/18/2012US20120263739 Anti integrin antibodies linked to nanoparticles loaded with chemotherapeutic agents
10/18/2012US20120263738 Multiplex dicer substrate rna interference molecules having joining sequences
10/18/2012US20120263737 Methods for inhibiting allograft rejection
10/18/2012US20120263736 Method for predicting and treating a sterile inflammation and discriminating between sterile and infective inflammation
10/18/2012US20120263735 Synthetic immunogenic glycoconjugate for melanoma immunotherapy
10/18/2012US20120263734 Compositions And Methods For The Therapy And Diagnosis Of Cytomegalovirus Infections
10/18/2012US20120263733 Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation
10/18/2012US20120263732 Cd40 antibody formulation and methods
10/18/2012US20120263731 HIGH CONCENTRATION ANTI-TNFalpha ANTIBODY LIQUID FORMULATIONS
10/18/2012US20120263730 Receptors of rspo2 and rspo3
10/18/2012US20120263729 Compositions and methods for treating cardiovascular disease
10/18/2012US20120263728 Method to generate antibodies to ion channels
10/18/2012US20120263727 Method to generate antibodies to ion channels
10/18/2012US20120263726 Pharmaceutical composition and method of inhibiting of production or amplifying of elimination of P24 protein
10/18/2012US20120263725 Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
10/18/2012US20120263724 Escherichia coli o157:h7 proteins and uses thereof
10/18/2012US20120263723 c-Met Antibodies
10/18/2012US20120263722 Dual Variable Domain Immunoglobulins and Uses Thereof
10/18/2012US20120263721 Therapeutic Combination and Methods of Treatment With a DLL4 Antagonist and an Anti-Hypertensive Agent
10/18/2012US20120263720 Novel Therapeutic and Diagnostic Means
10/18/2012US20120263719 Compositions and methods for treating aspergillosis
10/18/2012US20120263718 Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof
10/18/2012US20120263717 Humanized anti-fgf19 antagonists and methods using same
10/18/2012US20120263716 Method of treating cancers and a pharmaceutical composition that may be used in practicing said method
10/18/2012US20120263715 Topical Methods Of Treating RSV Infections And Related Conditions
10/18/2012US20120263714 Substituted halophenoxybenzamide derivatives
10/18/2012US20120263713 Combination therapy of an afucosylated CD20 antibody with fludarabine and/or mitoxantrone
10/18/2012US20120263712 Pyrrolidine-1,2-dicarboxamide derivatives
10/18/2012US20120263711 Engineering Fc Antibody Regions to Confer Effector Function
10/18/2012US20120263710 Administering anti-placental growth factor antibodies
10/18/2012US20120263709 Use of il-33 antagonists to treat fibrotic diseases
10/18/2012US20120263708 Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
10/18/2012US20120263707 Broad Spectrum ErbB Ligand Binding Molecules and Methods for Preparing and Using Them
10/18/2012US20120263706 Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
10/18/2012US20120263680 Compositions And Methods For Preventing Or Treating Diseases, Conditions, Or Processes Characterized By Aberrant Fibroblast Proliferation And Extracellular Matrix Deposition
10/18/2012US20120263679 Combinations Comprising Heterocyclic Inhibitors of MEK and Methods of Use Thereof
10/18/2012US20120263677 Combination of Local and Systemic Immunomodulative Therapies for Enhanced Treatment of Cancer
10/18/2012US20120263676 Compositions, methods and kits relating to her-2 cleavage
10/18/2012US20120263675 Bivalent diazo bicyclic smac
10/18/2012US20120263674 Pseudomonas exotoxin a with reduced immunogenicity
10/18/2012US20120263654 Melanoma specific biomarker
10/18/2012US20120263652 Targeted carriers for drug delivery across the gastrointestinal epithelium
10/18/2012US20120263647 Pro104 Antibody Compositions and Methods of Use
10/18/2012US20120263644 Treatment and diagnosis of inflammatory disorders and hiv
10/18/2012CA2832692A1 Combination vaccine
10/18/2012CA2832560A1 Formulations with reduced viscosity
10/18/2012CA2832307A1 Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
10/18/2012CA2831964A1 Fermentation process
10/18/2012CA2831258A1 Compositions for preventing and/or treating an infection by an hiv-1 virus
10/18/2012CA2830923A1 Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
10/18/2012CA2830786A1 Fusion proteins and combination vaccines comprising haemophilus influenzae protein e and pilin a
10/17/2012EP2511371A1 Anticancer anti-mortalin peptide antibodies
10/17/2012EP2511368A1 Recombinant measles virus useful as bivalent vaccine against measles and nipah virus infection
10/17/2012EP2511367A1 Recombinant measles virus useful as bivalent vaccine against measles and malaria infection
10/17/2012EP2511301A2 Human antibodies to ERBB2
10/17/2012EP2511299A1 Humanized anti-CD70 binding agents and uses thereof
10/17/2012EP2511295A1 Compositions for preventing and/or treating an infection by an HIV-1 virus
10/17/2012EP2511291A2 Chlamydia antigens
10/17/2012EP2510948A1 T cell activation inhibitor, pharmaceutical composition containing same, and screening method for t cell activation inhibiting substance
10/17/2012EP2510947A1 Compositions for immunising against Staphylococcus aureus
10/17/2012EP2510946A1 Conjugates of synthetic tlr agonists and uses therefor
10/17/2012EP2510945A1 Immunogens, compositions and uses thereof, method for preparing same
10/17/2012EP2510941A2 Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
10/17/2012EP2510934A1 Methods for promoting neurite outgrowth and survival of dopaminergic neurons
10/17/2012EP2510013A1 Pcsk9 antagonists
10/17/2012EP2510012A1 Anti-c4.4a antibodies and uses thereof
10/17/2012EP2510011A1 Monoclonal antibodies that bind b7h6 and uses thereof
10/17/2012EP2510009A1 Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
10/17/2012EP2510007A1 Neutralizing prolactin receptor antibodies and their therapeutic use
10/17/2012EP2510006A1 Neutralizing prolactin receptor antibodies and their therapeutic use
10/17/2012EP2510005A1 Neutralizing prolactin receptor antibodies and their therapeutic use
10/17/2012EP2510004A1 Neutralizing prolactin receptor antibodies and their therapeutic use
10/17/2012EP2510003A1 Neutralizing prolactin receptor antibodies and their therapeutic use
10/17/2012EP2510002A1 Neutralizing prolactin receptor antibodies and their therapeutic use
10/17/2012EP2510001A1 Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
10/17/2012EP2510000A1 Anti-inflammatory antibodies and uses therefor
10/17/2012EP2509999A1 Anti-inflammatory agents directed against citrullinated epitopes
10/17/2012EP2509630A1 Delivery system for cytotoxic drugs by bispecific antibody pretargeting
10/17/2012EP2509629A1 Dock-and-lock (dnl) complexes for delivery of interference rna
10/17/2012EP2509628A2 Sr-bi as a predictor of human female infertility and responsiveness to treatment
10/17/2012EP2509627A1 Methods for enhancing anti-tumor antibody therapy
10/17/2012EP2509626A1 Anti-vegf-c antibodies and methods using same
10/17/2012EP2509623A1 Methods and compositions using peroxiredoxin 1 (prx1) as an adjuvant
10/17/2012CN1823092B Therapy-enhancing glucan
10/17/2012CN1771338B High affinity anti-human IgE antibodies
10/17/2012CN102741295A Antigen presenting cell targeted anti-viral vaccines
10/17/2012CN102741292A A monoclonal antibody to cd44 for use in the treatment of head and neck squamous cell carcinoma
10/17/2012CN102741291A Neutralizing prolactin receptor antibodies and their therapeutic use
10/17/2012CN102741290A Monoclonal antibodies that bind B7H6 and uses thereof
10/17/2012CN102741289A Antibodies specific for claudin 6 (cldn6)
10/17/2012CN102741287A Antibody molecules having specificity for human OX40
10/17/2012CN102741285A Human IL-23 antigen binding proteins
10/17/2012CN102741281A Monoclonal antibodies against the pbp2-a protein and homologous sequences for the treatment of infections by and immunodiagnostics of bacteria of the firmicutes phylum
10/17/2012CN102741277A IFN[gamma]inhibitors in the treatment of motoneuron diseases
10/17/2012CN102741272A Peptides inhibiting adhesion of aspergillus fumigatus to cornea
1 ... 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 ... 1823